Upload
audra-garrett
View
217
Download
0
Embed Size (px)
Citation preview
Progress of the SNM Clinical Trials Network
Michael Graham, PhD, MDClinical Trials Network Co-Chair
SNM President
1
2
CTN Organizational Chart
Promote “The Practice of Clinical Trials” through:
•Accelerated clinical trials for investigational therapeutics
•Improved availability and performance of imaging biomarkers
•Increased number of imaging biomarkers available for clinical use
•Faster, more cost-effective drug development to facilitate patient access
Mission
3
• Provide an international registry of qualified and certified imaging centers through phantom utilization and ongoing assessment and monitoring
• Organize a manufacturing registry for production of and access to imaging biomarkers
• Provide site orientation and training programs to increase adherence to protocols; drive quality
• Support multisite clinical trials to gather standardized imaging data that will lead to improved efficiency and validity of using imaging biomarkers for therapeutic trials
• Collect safety and efficacy data of imaging biomarkers through a centralized IND
Overall Goals
4
• Consistent Growth
Network Registries (Dec 09)
5
• Pharma companies interested in using imaging technology in drug discovery and development
• Focus on multicenter clinical trials ~ 1 per year• Credentialed academic institutions to conduct
studies— Expertise— Technologies/applied standards
• Site orientation and training programs― Certified technologists
Imaging Biomarker Development Network
6
• Registration in the CTN site database: online completion of site-specific information
(e.g., equipment, personnel, research experience)
• Scanner Validation via the CTN Phantom Program
• Site Qualification: meeting a minimum of pre-determined requirements related to research infrastructure, validated equipment and access to experimental imaging agents.
Site Qualification Process
7
• FDG• FLT• FDOPA• FAZA• FMISO• Ga-68 octreotide• FES• FHDT• C-11 acetate
No company owns the rights
No company will solely benefit
No company will sponsor the trials
Centralized INDDrugs without parentage
8
Benefits• Mechanism of access to
radiopharmaceuticals without having to perform pre-clinical studies
• Access to standardized imaging protocols
• Decreased cost associated with pharmaceutical IND by not having to file a second tracer IND
• Shared responsibility for reporting of safety and efficacy data
Centralized IND
9
Considerations• Community Needs
– Therapeutic areas of interest– Current pharmaceutical development
• Tracer Availability– Location of manufacturers– Agent viability
1. Access to Pre-clinical data
Centralized IND Selection
10
Centralized IND Selection
11
Areas of Interest
Hypoxia
Amyloid
Lipid Synthesis
Protein Synthesis
Dopaminergic Receptors
Estrogen Receptors
Angiogenesis
Apoptosis
Testosterone Receptors
First Multicenter IND
3'-deoxy-3'-[18F] fluorothymidine (FLT) 12
O
F
N
NH
HO
OMe
O
F
Why FLT?
• Community interest
• Investigational PET imaging biomarker
• Literature reports of “potential” for demonstrating tumor proliferation
• Potential as a surrogate marker for evaluating investigational as well
as existing oncology therapeutics
• Broadly applicable to lung, breast, esophageal, GI, brain, lymphoma
First Multicenter IND: [F-18] FLT
13
F-MISO
Second Multicenter IND
14
Why F-MISO?
• Community interest
• Availability
• Demonstrated ability to image and quantify hypoxia
Second Multicenter IND
15
• First SNM multicenter IND for an investigational imaging biomarker• First three founding members from the pharmaceutical
development community on board• 200+ members of both the imaging site and manufacturers
registries• Over 25% participation from outside the U.S.• Development and launch of a clinical oncology phantom program• Many on-going educational activities to inform about the Network
and advance the awareness and understanding of the “Practice of Clinical Trials” within the imaging community– Community Workshop to be held Feb 1-2, 2010 in Albuquerque
Accomplishments
16
• One new IND per year (next submission expected by mid-2010)
• Expanded phantom program to include cardiac and brain qualifications
• Reach beyond PET biomarkers
• Assist with imaging protocol development, conduct, and integration with imaging CROs
• Expand multicenter IND capability for imaging biomarkers– Non-proprietary– Proprietary– Individual academic-investigator driven
Long-Term Vision
17
www.snm.org/clinicaltrials